Xeljanz and Metastases to pancreas - a phase IV clinical study of FDA data


Metastases to pancreas is reported only by a few people who take Xeljanz.

The phase IV clinical study analyzes which people take Xeljanz and have Metastases to pancreas. It is created by eHealthMe based on reports of 192,294 people who have side effects while taking Xeljanz from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Oct, 01, 2022

192,294 people reported to have side effects when taking Xeljanz.
Among them, 2 people (0.0%) have Metastases to pancreas.

What is Xeljanz?

Xeljanz has active ingredients of tofacitinib citrate. It is often used in rheumatoid arthritis. eHealthMe is studying from 192,425 Xeljanz users for its effectiveness, alternative drugs and more.

What is Metastases to pancreas?

Metastases to pancreas (cancer spreads to pancreas) is found to be associated with 287 drugs and 153 conditions by eHealthMe.

Number of Xeljanz and Metastases to pancreas reports submitted per year:

Could Xeljanz cause Metastases to pancreas?

Time on Xeljanz when people have Metastases to pancreas *:

  • < 1 month: 0.0 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 100 %
  • 10+ years: 0.0 %

Gender of people who have Metastases to pancreas when taking Xeljanz *:

  • female: 50 %
  • male: 50 %

Age of people who have Metastases to pancreas when taking Xeljanz *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 0.0 %
  • 60+: 100 %

Common drugs people take besides Xeljanz *:

  1. Nexium: 1 person, 50.00%
  2. Lyrica: 1 person, 50.00%

Common side effects people have besides Metastases to pancreas *:

  1. White Blood Cell Count Decreased: 1 person, 50.00%
  2. Glucose Urine Present: 1 person, 50.00%
  3. Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 1 person, 50.00%
  4. Aspartate Aminotransferase Increased: 1 person, 50.00%
  5. Blood Albumin Decreased: 1 person, 50.00%
  6. Blood Alkaline Phosphatase Increased: 1 person, 50.00%
  7. Blood Chloride Increased: 1 person, 50.00%
  8. Blood Glucose Increased: 1 person, 50.00%
  9. Blood Lactate Dehydrogenase Increased: 1 person, 50.00%
  10. Blood Urine Present: 1 person, 50.00%

Common conditions people have *:

  1. Osteoporosis (bones weak and more likely to break): 1 person, 50.00%
  2. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 50.00%

* Approximation only. Some reports may have incomplete information.

Do you take Xeljanz and have Metastases to pancreas?

Check whether Metastases to pancreas is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Metastases to pancreas and when was it recovered:

Expand to all the drugs that have ingredients of tofacitinib citrate:

Alternative drugs to, pros and cons of Xeljanz:

Common Xeljanz side effects:

Browse all side effects of Xeljanz:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Metastases to pancreas treatments and more:

COVID vaccines that are related to Metastases to pancreas:

All the drugs that are associated with Metastases to pancreas:

All the conditions that are associated with Metastases to pancreas:

How the study uses the data?

The study uses data from the FDA. It is based on tofacitinib citrate (the active ingredients of Xeljanz) and Xeljanz (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: